What is the treatment for hypercalcemia (elevated calcium level of 13)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Treatment for a calcium level of 13 mg/dL requires immediate medical attention with aggressive intravenous fluid rehydration and medications like bisphosphonates, specifically zoledronic acid, to inhibit bone resorption and reduce calcium levels. The management of hypercalcemia involves a multifaceted approach, including hydration, bisphosphonates, denosumab, steroids, and/or calcitonin, as recommended by the NCCN MM Panel members 1.

Key Considerations

  • Aggressive intravenous fluid rehydration with normal saline at 200-300 mL/hour to increase calcium excretion through the kidneys
  • Bisphosphonates, such as zoledronic acid 4 mg IV, to inhibit bone resorption, with effects beginning within 2-3 days
  • Calcitonin (4 IU/kg subcutaneously every 12 hours) may be added for rapid but short-term calcium reduction
  • Loop diuretics like furosemide (20-40 mg IV) can be used after adequate hydration is achieved
  • Identification and treatment of the underlying cause of hypercalcemia, such as hyperparathyroidism or malignancy
  • Discontinuation of calcium supplements, vitamin D, and medications that can raise calcium levels
  • Monitoring of symptoms like confusion, weakness, constipation, and cardiac abnormalities

Additional Recommendations

  • Plasmapheresis should be used as adjunctive therapy for symptomatic hyperviscosity 1
  • Erythropoietin therapy may be considered for anemic patients, especially those with renal failure 1
  • Prophylactic anti-coagulation agents are recommended when IMiDs are used in combination therapy during induction 1
  • Intravenous immunoglobulin therapy should be considered for recurrent, life-threatening infections 1
  • Pneumocystis jiroveci pneumonia, herpes zoster, and antifungal prophylaxis is recommended if high-dose dexamethasone is used 1

From the FDA Drug Label

The recommended dose of pamidronate disodium in severe hypercalcemia (corrected serum calcium* >13.5 mg/dL) is 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours. The treatment for a calcium level of 13 is pamidronate disodium 90 mg as a single-dose intravenous infusion over 2 to 24 hours 2.

  • Key points:
    • Dose: 90 mg
    • Administration: single-dose intravenous infusion
    • Duration: 2 to 24 hours
    • Indication: severe hypercalcemia (corrected serum calcium >13.5 mg/dL)

From the Research

Treatment for Calcium of 13

  • The treatment for hypercalcemia, which is characterized by elevated calcium levels in the blood, typically starts with hydration 3, 4, 5.
  • Loop diuretics may be required in individuals with renal insufficiency or heart failure to prevent fluid overload 3.
  • Calcitonin is administered for the immediate short-term management of severe symptomatic hypercalcemia 3.
  • For long-term control of severe or symptomatic hypercalcemia, the addition of bisphosphonate is typically required 3, 4, 5.
  • Among intravenous bisphosphonates, zoledronic acid or pamidronate are the agents of choice 3, 4, 5.
  • Glucocorticoids are effective in hypercalcemia due to lymphoma or granulomatous diseases 3, 4.
  • Dialysis is generally reserved for those with severe hypercalcemia complicated with kidney failure 3, 4.

Specific Treatment Approaches

  • For severe hypercalcaemia secondary to primary hyperparathyroidism, saline hydration, and zoledronic acid have been shown to be effective 5.
  • Furosemide is not recommended for the treatment of hypercalcemia, as its effectiveness has not been proven and it may not provide additional benefits compared to saline hydration alone 5, 6.
  • The use of furosemide in the management of hypercalcemia should no longer be recommended 6.

Additional Considerations

  • It is essential to identify and treat the underlying cause of hypercalcemia 3, 4.
  • The prognosis for asymptomatic primary hyperparathyroidism is excellent with either medical or surgical management, while hypercalcemia of malignancy is associated with poor survival 4.
  • Drug-related hypercalcemia can occur due to various medications, including vitamin D supplements, thiazide diuretics, and lithium, and requires optimal medical management 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hypercalcemia: an evidence-based approach to clinical cases.

Iranian journal of kidney diseases, 2009

Research

Hypercalcemia: A Review.

JAMA, 2022

Research

Drug-Related Hypercalcemia.

Endocrinology and metabolism clinics of North America, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.